Clinical trial
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic…
NCT00052832 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00052832 |
|---|---|
| Title | Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| Official title | Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Dietary Supplement |
| Interventions | doxercalciferol |
| Start date | Sep 1, 2002 |
| Primary completion | Jul 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: